Market revenue in 2022 | USD 335.2 million |
Market revenue in 2030 | USD 530.5 million |
Growth rate | 5.9% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 55.7% in 2022. Horizon Databook has segmented the Brazil hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is the largest market for hormone replacement therapy due to the rising geriatric population and various initiatives undertaken by the government to support treatment associated with women’s health including HRT medicines for women’s health.
According to Brazilian Institute o f Geography and Statistics, around one-fourth of the female population in Brazil is aged 4 5 or older. Given these circumstances and projections, the number of women going through menopause in Brazil is estimated to grow as the population ages and individuals live longer.
The incidence of hypothyroidism was lesser in men when compared to women with a ratio of 1:36. Thus, increasing prevalence of hypothyroidism is boosting the demand for thyroid hormone replacement therapy, which is used t o treat patients with hypothyroidism, thereby driving market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Brazil hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account